Onconetix (NASDAQ:ONCO – Get Free Report) posted its quarterly earnings results on Monday. The company reported ($76.01) earnings per share for the quarter, topping the consensus estimate of ($45,050.00) by $44,973.99, FiscalAI reports. Onconetix had a negative return on equity of 91.95% and a negative net margin of 1,575.89%. The company had revenue of $0.10 million during the quarter, compared to the consensus estimate of $0.02 million.
Onconetix Stock Down 9.3%
Shares of NASDAQ:ONCO traded down $0.30 during midday trading on Monday, reaching $2.91. 62,174 shares of the company traded hands, compared to its average volume of 167,959. The firm’s fifty day moving average price is $6.09 and its two-hundred day moving average price is $106.54. The firm has a market capitalization of $1.72 million, a price-to-earnings ratio of 0.00 and a beta of 2.62. Onconetix has a 12 month low of $2.76 and a 12 month high of $1,610.00.
Analysts Set New Price Targets
A number of brokerages recently issued reports on ONCO. Wall Street Zen upgraded Onconetix from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. Weiss Ratings upgraded shares of Onconetix from a “sell (e)” rating to a “sell (e+)” rating in a research report on Thursday, October 29th. One research analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, the stock presently has an average rating of “Sell”.
Check Out Our Latest Stock Analysis on ONCO
Onconetix Company Profile
Onconetix, Inc. is a biotechnology company focused on cancer-related diagnostics and therapeutics, with an emphasis on prostate health. Its portfolio includes Proclarix, a blood-based diagnostic test developed to help assess prostate cancer risk. Proclarix was developed by Swiss company Proteomedix, which Onconetix acquired in 2023. The test has received a CE mark for use in Europe; its availability and regulatory status may differ in other markets. Onconetix was formerly known as Blue Water Biotech before adopting its current name in 2024.
Read More
- Five stocks we like better than Onconetix
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Onconetix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Onconetix and related companies with MarketBeat.com's FREE daily email newsletter.
